{"created":"2022-01-28T01:03:07.608404+00:00","id":2005147,"links":{},"metadata":{"_buckets":{"deposit":"b79be6db-5f52-4b66-876e-968bfda85638"},"_deposit":{"id":"2005147","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2005147"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02005147","sets":["1642838403123","1642838403551:1642838407795"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"アンジオテンシン1-7のレニンアンジオテンシン系抑制による心血管病治療への貢献","subitem_1551255648112":"ja"},{"subitem_1551255647225":"Role of Angiotensin (1-7) in therapeutic application of inhibition of rennin-angiotensin system in man","subitem_1551255648112":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"植田, 真一郎","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"安成, 憲一","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"島袋, 充生","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"瀧下, 修一","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"Ueda, Shinichiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yasunari, Kenichi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Shimabukuro, Michio","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takishita, Shuichi","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_1522299639480":"open access","subitem_1600958577026":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"アンジオテンシン(1-7)"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"アンジオテンシンII"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"ブラジキニン"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"酸化ストレス"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"抗酸化作用"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"NOクランプ法"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"降圧利尿薬臨床試験"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"angiotensin(1-7)"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"Angiotensin II"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"bradykinin"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"oxidative stress"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"AGE inhibitor"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"Nitric Oxide"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"RCT of diuretics"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"ACE阻害薬"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"心不全"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"プレシスモグラフ"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"アンジオテンシン変換酵素"},{"subitem_1522299896455":"ja","subitem_1522300014469":"Other","subitem_1523261968819":"前腕血流量"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"科研費番号: 13670734","subitem_description_type":"Other"},{"subitem_description":"平成13年度～平成15年度科学研究費補助金(基盤研究(C)(2))研究成果報告書","subitem_description_type":"Other"},{"subitem_description":"研究概要:1.アンジオテンシン(1-7)の血管作用アンジオテンシン(1-7)をbrachial arteryより注入し、ヒト前腕抵抗血管におけるブラジキンンなどとの相互作用を検討した。アンジオテンシン(1-7)はそれ自体では血管拡張作用を有しないが、ブラジキニンの血管拡張作用を有意に増強した。この作用はACE阻害薬の投与下およびL-NMMAを用いてNOの産生抑制を行った場合も消失した。 2.ヒト血管NO研究におけるNOクランプ法のvalidation study ヒト抵抗血管においてLNMMAを動注してNOに関する実験を行う時、NOクランプ法を用いる妥当性を証明した。 3.アンジオテンシンIIの酸化ストレス増強作用と、アンジオテンシン(1-7)の抗酸化作用:in vivoおよびin vitroの検討ヒトマクロファージのモデルを作り、アンジオテンシンIIによる酸化ストレスをフローサイトメトリーで測定し、アンジオテンシン(1-7)の作用を検討した。アンジオテンシン(1-7)は、アンジオテンシンIIによる酸化ストレスの増加を用量依存性に抑制した。我々はまたアンジオテンシンIIは前腕抵抗血管においておそらく活性酸素産生増大によりNOドナーによる血管拡張作用を減弱させることを示したが、この実験系においてアンジオテンシン(1-7)はこのアンジオテンシンIIによる酸化ストレス増大を用量依存性に抑制した。 4.ACE阻害薬投与中の高血圧患者および心不全患者における血中アンジオテンシン(1-7)濃度 ACE阻害薬投与中の高血圧患者では非投与患者に比べ血中アンジオテンシンII濃度は差がないが、アンジオテンシン(1-7)濃度は有意に高値であった。またカプトプリル急性投与後の血圧の低下はアンジオテンシン(1-7)濃度上昇と相関した。心不全患者においてアンジオテンシン(1-7)は正常の 20-40倍と高値を示した。 5.降圧利尿薬臨床試験におけるレニンアンジオテンシン系マーカーの測定昨年開始された降圧利尿薬臨床試験のサブ研究としてアンジオテンシン(1-7)測定を予定している。","subitem_description_type":"Other"},{"subitem_description":"要約(欧文):1.Interaction of Angiotensin(1-7) with bradykin and other vasoactive peptides in human resistant vessels in vivo Angiotensin(1-7) significantly potentiated vasodilating effect of bradykinin in dose-dependent manner possibly through NO system. This result is completely consistent with previous results from studies in isolated vessels. 2.Validation of NO clamp technique in human NO research in vivo We evaluated validity and feasibility of NO damp technique for NO research using L-NMMA for NOS inhibition. 3.Anticoxidant effect of Angiotensin(1-7) in vitro and in vivo We showed Angiotensin II attenuated vasodilating effect of a NO donor possibly through increased production of superoxide in human resisitant vessels. This effect was antagonized by co-infusion of Angiotensin(1-7) in dose dedpendent manner. Angiotensin(1-7) was also found to inhibit increased oxidative stress by Angiotensin II in cultured human THP-1 cells. 4.Increased Angiotensin(1-7) levels in patients with hypertension receiving ACE inhibitors. The single dose of captopril significantly elevated plasma levels of angiotensin-(1-7) in hypertensives and normal volunteers. There was highly significant correlation between changes in plasma levels of angiotensin-(1-7) and blood pressure. Plasma angiotensin-(1-7) levels in hypertensive patients chronically receiving ACE inhibitors were significantly higher than those without AGE inhibitors while there was no significant difference in plasma Angiotensin II levels. Either acute or chronic treatment with ACE inhibitors was associated with increased plasma levels of angiotennsin-(1-7), which may contribute to effects of ACF inhibitions.","subitem_description_type":"Other"},{"subitem_description":"未公開：P.4以降(別刷論文のため)","subitem_description_type":"Other"},{"subitem_description":"研究報告書","subitem_description_type":"Other"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_1522300295150":"ja","subitem_1522300316516":"植田真一郎"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_1551255818386":"eng"}]},"item_1617186783814":{"attribute_name":"Identifier","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/20.500.12000/13947"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_1522646500366":"NCID","subitem_1522646572813":"BA74808880"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2004-05","bibliographicIssueDateType":"Issued"}}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_1522305645492":"VoR","subitem_1600292170262":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"13670734.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2005147/files/13670734.pdf"},"version_id":"e47c2839-6829-48e9-8b63-f2fb2e3357f4"}]},"item_title":"アンジオテンシン1-7のレニンアンジオテンシン系抑制による心血管病治療への貢献","item_type_id":"15","owner":"1","path":["1642838403123","1642838407795"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2009-12-15"},"publish_date":"2009-12-15","publish_status":"0","recid":"2005147","relation_version_is_last":true,"title":["アンジオテンシン1-7のレニンアンジオテンシン系抑制による心血管病治療への貢献"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2022-10-31T02:30:31.930421+00:00"}